[go: up one dir, main page]

PE20010685A1 - Composicion que comprende un polipeptido antagonista del receptor de interleuquina 1 y una diarilsulfonilurea como inhibidor del procesamiento y la liberacion de il-1 - Google Patents

Composicion que comprende un polipeptido antagonista del receptor de interleuquina 1 y una diarilsulfonilurea como inhibidor del procesamiento y la liberacion de il-1

Info

Publication number
PE20010685A1
PE20010685A1 PE2000000942A PE0009422000A PE20010685A1 PE 20010685 A1 PE20010685 A1 PE 20010685A1 PE 2000000942 A PE2000000942 A PE 2000000942A PE 0009422000 A PE0009422000 A PE 0009422000A PE 20010685 A1 PE20010685 A1 PE 20010685A1
Authority
PE
Peru
Prior art keywords
interleuquin
release
processing
urea
hydroxy
Prior art date
Application number
PE2000000942A
Other languages
English (en)
Inventor
Mark Anthony Dombroski
Bruce Henry Littman
Thasia Louise Goodwin Woodworth
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20010685A1 publication Critical patent/PE20010685A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A USO DE UNA COMPOSICION QUE COMPRENDE: a)UN POLIPEPTIDO ANTAGONISTA DEL RECEPTOR DE INTERLEUQUINA 1 (IL-1ra), DE PREFERENCIA DE UNA SECUENCIA (ID SEQ N°2) DE 169 AMINOACIDOS; b)UN AGENTE NO ESTEROIDEO QUE INHIBE EL PROCESAMIENTO Y LA LIBERACION DE IL-1 TAL COMO DIARILSULFONILUREA R1-(O=)S(=O)-NH-C(=O)-NH-R2; DONDE R1 Y R2 SON UN GRUPO DE FORMULA II EN LA QUE LAS LINEAS --- REPRESENTAN DOBLES ENLACES OPCIONALES; n ES 0-3; A, B, D, E Y G SON O, S, N, CR5R6; R5 Y R6 SON H, ALQUILO C1-C6, HALOGENO, CIANO, AMINO, OH, ENTRE OTROS, SIENDO COMPUESTOS SELECCIONADOS 1-(1,2,3,5,6,7-HEXAHIDRO-s-INDACEN-4-IL)-3-[4-(1-HIDROXI-1-METIL-ETIL)-FURANO-2-SULFONIL]-UREA, 1-(2,6-DIISOPROPIL-FENIL)-3-[4-(1-HIDROXI-1-METIL-ETIL-FURANO-2-SULFONIL]-UREA, 1-(4-CLORO-2,6-DIISOPROPIL-FENIL)-3-[3-(HIDROXI-1-METIL-ETIL)-BENCENOSULFONIL]-UREA, ENTRE OTROS. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE TRASTORNOS INFLAMATORIOS TAL COMO ARTRITIS REUMATOIDE, OSTEOARTRITIS, ASMA, NEURODEGENERACION, ENTRE OTROS
PE2000000942A 1999-09-14 2000-09-12 Composicion que comprende un polipeptido antagonista del receptor de interleuquina 1 y una diarilsulfonilurea como inhibidor del procesamiento y la liberacion de il-1 PE20010685A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15401099P 1999-09-14 1999-09-14

Publications (1)

Publication Number Publication Date
PE20010685A1 true PE20010685A1 (es) 2001-07-03

Family

ID=22549650

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000942A PE20010685A1 (es) 1999-09-14 2000-09-12 Composicion que comprende un polipeptido antagonista del receptor de interleuquina 1 y una diarilsulfonilurea como inhibidor del procesamiento y la liberacion de il-1

Country Status (13)

Country Link
EP (1) EP1214087A1 (es)
JP (1) JP2003509378A (es)
AR (1) AR033650A1 (es)
AU (1) AU6464400A (es)
BR (1) BR0014003A (es)
CA (1) CA2383026A1 (es)
CO (1) CO5190701A1 (es)
EC (1) ECSP003652A (es)
GT (1) GT200000155A (es)
PA (1) PA8502901A1 (es)
PE (1) PE20010685A1 (es)
TN (1) TNSN00183A1 (es)
WO (1) WO2001019390A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57852B1 (sr) 2004-04-02 2018-12-31 Swedish Orphan Biovitrum Ab Publ Postupci za smanjenje agregacije il-1ra
WO2008129288A2 (en) * 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
PT3259253T (pt) * 2015-02-16 2020-03-11 Univ Queensland Sulfonilureias e compostos relacionados e uso dos mesmos
HK1257569A1 (zh) 2016-02-16 2019-10-25 The University Of Queensland 磺醯脲和相关化合物及其用途
MA56008A (fr) * 2016-04-18 2022-04-06 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
MX2019008592A (es) 2017-01-23 2019-11-21 Genentech Inc Compuestos químicos como inhibidores de la actividad de la interleuquina-1.
CA3059458A1 (en) 2017-05-24 2018-11-29 The University Of Queensland Novel compounds and uses
EP3634951B8 (en) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Novel substituted sulfoximine compounds
WO2019008029A1 (en) 2017-07-07 2019-01-10 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
JP7235742B2 (ja) 2017-07-07 2023-03-08 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
CN111094243B (zh) 2017-07-24 2023-09-05 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
RU2020110219A (ru) * 2017-08-15 2021-09-17 Инфлазоум Лимитед Сульфонилмочевины и сульфонилтиомочевины в качестве ингибиторов nlrp3
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
CA3071145A1 (en) 2017-08-15 2019-02-21 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
EP3692020A1 (en) 2017-10-03 2020-08-12 Inflazome Limited Novel compounds
RU2020115098A (ru) 2017-11-09 2021-12-10 Инфлазоум Лимитед Соединения новых сульфонамидкарбоксамидов
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP3759090A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
US12168653B2 (en) 2018-03-02 2024-12-17 Inflazome Limited Sulfonamide derivates as NLRP3 inhibitors
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
GB201806578D0 (en) * 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
EP3817817A1 (en) 2018-07-03 2021-05-12 Novartis AG Nlrp modulators
JP7411631B2 (ja) 2018-07-20 2024-01-11 エフ. ホフマン-ラ ロシュ アーゲー インターロイキン-1活性の阻害剤としてのスルホニル尿素化合物
WO2020018975A1 (en) 2018-07-20 2020-01-23 Genentech, Inc. Sulfonimidamide compounds as inhibitors of interleukin-1 activity
CA3108948A1 (en) 2018-08-15 2020-02-20 Inflazome Limited Novel sulfonamideurea compounds
EP3870565A1 (en) * 2018-10-24 2021-09-01 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
CA3126467A1 (en) 2019-01-14 2020-07-23 Cadila Healthcare Limited Novel substituted sulfonylurea derivatives
CN111875694B (zh) * 2020-05-25 2022-07-05 北京伟德杰生物科技有限公司 一种白细胞介素-1受体拮抗剂以及包含其的融合蛋白

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
DE69729762T2 (de) * 1997-01-29 2005-07-14 Pfizer Inc. 4-Substituiertes Furan-2-sulfonamid und dessen Verwendung in der Herstellung von Sulfonylharnstoff-Derivate
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins

Also Published As

Publication number Publication date
BR0014003A (pt) 2002-05-21
CO5190701A1 (es) 2002-08-29
CA2383026A1 (en) 2001-03-22
TNSN00183A1 (fr) 2005-11-10
EP1214087A1 (en) 2002-06-19
GT200000155A (es) 2002-03-08
ECSP003652A (es) 2002-04-23
PA8502901A1 (es) 2002-02-21
AU6464400A (en) 2001-04-17
WO2001019390A1 (en) 2001-03-22
AR033650A1 (es) 2004-01-07
JP2003509378A (ja) 2003-03-11

Similar Documents

Publication Publication Date Title
PE20010685A1 (es) Composicion que comprende un polipeptido antagonista del receptor de interleuquina 1 y una diarilsulfonilurea como inhibidor del procesamiento y la liberacion de il-1
PE20040840A1 (es) Derivados de 4-oxoquinolina como inhibidores de la integrasa del vih
AR038563A1 (es) Composicion de ziprasidona y controles sinteticos
ATE420644T1 (de) Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
DE602004012858D1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
MX2007013065A (es) Derivados de dihidrobenzofurano y usos de los mismos.
ATE290059T1 (de) Tensidzusammensetzung enthaltend geminitenside und co-amphiphile, ihre herstellung und ihre verwendung
BR0007595A (pt) 4-(heterociclisulfonamido)-5-metóxi-6-(2-metoxifenó xi)-2-fenil-ou piridilpirimidinas como antagonistas de receptor de endotelina
NO20063470L (no) Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister
BRPI0413305A (pt) compostos azabicìclicos fundidos que inibem o receptor de subtipo de receptor de vanilóide 1 (vr1)
AR028824A1 (es) Compuestos antagonistas npy-5 y su uso en la manufactura de medicamentos.
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
BR0315644A (pt) Piperazinil e diazapanil benzamidas e benzotioamidas
UY28150A1 (es) Agentes terapeuticos
DE602006007556D1 (de) Heteroarylsulfonylstilbene als 5-ht2a-antagonisten
PE20060298A1 (es) Derivados de acido carboxilico de bencimidazolona
PE20030872A1 (es) Composicion farmaceutica del agonista parcial de 5ht4 tegaserod
SE0403171D0 (sv) New compounds
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
PE16299A1 (es) Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoreceptores
PE83999A1 (es) Azetidinas
PL374019A1 (en) Benzoxazine derivatives as 5-ht6 modulators and uses thereof
BR0211761A (pt) depsipeptìdeos e processos para preparar os mesmos
PE20030974A1 (es) Agonistas del receptor 2 del factor liberador de la corticotropina
UY27232A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos

Legal Events

Date Code Title Description
FC Refusal